SARS-CoV-2细胞受体的研究进展  

Recent progress on cell receptors for SARS-CoV-2

作　　者：陈生林[1] 肖蔓 李赵忠 徐志凯 韩起 冯东方[1] 邓雁 殷作明[1] CHEN Shenglin;XIAO Man;LI Zhaozhong;XU Zhikai;HAN Qi;FENG Dongfang;DENG Yan;YIN Zuoming(General Hospital of Tibet Military Area Command of PLA,Lhasa 850007,Tibet Autonomous Region,China;Chengdu Western Hospital,Chengdu 610036,Sichuan Province,China;General Hospital of Western Theater Command of PLA,Chengdu 610083,Sichuan Province,China)

机构地区：[1]中国人民解放军西藏军区总医院,西藏拉萨850007 [2]成都西区医院,四川成都610036 [3]中国人民解放军西部战区总医院,四川成都610083

出　　处：《微生物与感染》2023年第1期46-54,共9页Journal of Microbes and Infections

基　　金：军队重点课题(BLB18J008)。

摘　　要：严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)是引起2019冠状病毒病(coronavirus disease 2019,COVID-19)的病原体,在人群中广泛持久传播,对人类健康和社会经济造成了巨大危害。目前,针对COVID-19的治疗尚无特异高效的抗病毒药物。病毒为实现寄生感染,通常先与宿主细胞膜表面受体结合,进而内化入胞。因此,SARS-CoV-2受体决定着病毒的感染特性和宿主范围,对其进行研究和解析是战胜SARS-CoV-2感染的一个关键手段。SARS-CoV-2受体的发现和鉴定,将为COVID-19提供新的治疗靶点。本文主要对SARS-CoV-2入侵受体及黏附受体的研究进展进行综述。Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the causative agent of the coronavirus disease 2019(COVID-19),which spreads rapidly in humans and endangers global health and economy.There are no specific and effective antiviral drugs for the treatment of COVID-19 currently.To infect host cells successfully for a virus,receptor binding and virus internalization are considered to be the initial steps.A key to combat SARS-CoV-2 infection is to investigate the viral receptors,which determine its infectivity and host range.The discovery and identification of cell receptors for SARS-CoV-2 will provide new therapeutic targets for COVID-19.This article reviews the recent findings on the entry and attachment receptors for SARS-CoV-2.

关 键 词：严重急性呼吸综合征冠状病毒2 入侵 受体 黏附受体 刺突蛋白 受体结合域 

分 类 号：R373.1[医药卫生—病原生物学]